Immunocore Holdings (IMCR) Gross Profit (2023 - 2026)

Immunocore Holdings has disclosed Gross Profit across 4 years of filings, most recently posting $106.2 million for Q1 2026.

• Gross Profit for Q1 2026 came in at $106.2 million, up 14.18% year-over-year; the trailing twelve-month figure through Mar 2026 was $408.1 million (up 23.57% YoY), and the FY2025 annual result was $394.9 million, up 28.44% from the prior year.
• Gross Profit came in at $106.2 million for Q1 2026 at Immunocore Holdings, up from $101.8 million in the prior quarter.
• In the past five years, Gross Profit ranged from a high of $106.2 million in Q1 2026 to a low of $54.4 million in Q1 2023.
• The 4-year median for Gross Profit is $79.8 million (2024), against an average of $81.3 million.
• Across the five-year window, Gross Profit jumped 32.44% in 2025 and gained 14.18% in 2026, its largest moves.
• Immunocore Holdings' Gross Profit stood at $70.0 million in 2023, then grew by 19.67% to $83.7 million in 2024, then climbed by 21.56% to $101.8 million in 2025, then increased by 4.39% to $106.2 million in 2026.
• The last three Gross Profit figures came in at $106.2 million (Q1 2026), $101.8 million (Q4 2025), and $103.2 million (Q3 2025), per Business Quant data.